BioSpace News Archive

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) today reported financial results and operating highlights for the first quarter ended March 31, 2023.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company’s novel, patented1 AlloX2 Pro Tissue Expander.

Sonoma Pharmaceuticals, Inc. announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Charles River Laboratories International, Inc. and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy and other forms of PLA2G6-related neurodegeneration, announced a plasmid DNA manufacturing alliance.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Elevation Oncology, Inc. announced the pricing of an underwritten public offering of 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000 shares of common stock and accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant sold.

Innate Pharma SA is pleased to share Sanofi’s news that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported that sales of the antifungal Cresemba® by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling USD 26.25 million to Basilea.

Ionis Pharmaceuticals, Inc. announced the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706, an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting.